NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

001690-DK

Sponsoring Institute

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18 Years
Max Age: 65 Years

Referral Letter Required

No

Population Exclusion(s)

Pregnant Women;
Adults who are or may become unable to consent;
Children

Keywords

Ketogenic Diet;
Sleep;
Energy Expenditure;
Supplement;
Calories

Recruitment Keyword(s)

None

Condition(s)

Overweight;
Obesity

Investigational Drug(s)

None

Investigational Device(s)

None

Intervention(s)

Other: Standard Diet
Other: Ketogenic Diet
Dietary Supplement: Placebo
Dietary Supplement: Nicotinamide Riboside

Supporting Site

National Institute of Diabetes and Digestive and Kidney Diseases

Background:

At least 30% of Americans have fatty liver disease. This means that they store too much fat in the liver. At the moment lifestyle changes are the only way to treat this problem.

Objective:

To test how (1) a low-carbohydrate diet and (2) a supplement called nicotinamide riboside (NR) affect how a person s body uses dietary fat.

Eligibility:

Men aged 18 to 65 and women aged 18 to 50 who are healthy volunteers with a body mass index (height to weight ratio) of 25 or more. Adults with maturity-onset diabetes of the young type 2 (MODY2) are also needed.

Design:

Participants with diabetes will have 1 screening visit and a 9-day clinic stay. Healthy volunteers will have 1 screening visit and 2 clinic stays of 1 to 2 weeks each.

During screening, all participants will have a physical exam with blood and urine tests. They will have their heart rhythm measured while riding a gym bike.

NR is a pill taken by mouth. Only healthy volunteers will take the NR, for 14 days at a time, during 1 clinic stay. During their other stay, they will take placebos; these are pills that look like the study supplement but contain no NR.

During each clinic stay, all participants will eat a normal American diet. Then they will eat a ketogenic low-carb diet for 5 days.

Participants will have many tests, including:

Sleeping every night and having two 24-hour stays in a special room that measures the gases their body uses and produces.

Drinking a high-fat shake, then remaining seated for 5 hours while their blood and breath are monitored.

Having a substance injected into the arm and remaining seated for 3 hours while their blood is measured.

Wearing monitors to measure their activity levels. Another monitor will measure their blood glucose levels.

Having imaging scans.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

1. Meet one of the following:

a. Adult males aged 18-65 years

b. Pre-menopausal adult females aged 18-50 years

c. Adult males aged 18-65 years with diagnosed maturity-onset diabetes of the young type 2 (MODY2) or pre-menopausal adult females aged 18-50 years with diagnosed MODY2

2. Weight stable (< +/- 5 % body weight change over past 6 months) as determined by volunteer report

3. Body mass index (BMI) >= 25 kg/m^2

4. Able to cycle at a moderate rate and intensity with a HR equal to or greater than 0.3x(220-age-HRrest)+HRrest but not exceeding 0.4x(220-age-HRrest)+HRrest with no signs of arrhythmia

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Taking prescription medications or other drugs or supplements that may influence energy metabolism or nutrient digestion or absorption (including, but not limited to, diet/weight-loss medication or other medications at the discretion of the PI and/or study team)

2. Indicators of liver disease; combination of both albumin < 2.8 mg/mL and bilirubin > 3 mg/mL

3. Individuals with significant medical comorbidities (e.g., non-MODY2 diabetes, NYHA Class >II heart failure, or CKD Stage II or worse, or American Society of Anesthesiologists Physical Status Class 3 or above)

4. Individuals taking prescription medications to treat hypertension in participants without MODY2

5. Participating in a regular exercise program (> 2h/week of vigorous activity) as determined by volunteer report

6. Positive pregnancy test (only for people who can get pregnant)

7. Hematocrit < 40% (men only)

8. Hematocrit <37% (women only)

9. Caffeine consumption > 300 mg/day as determined by volunteer report

10. Alcohol consumption > 3 drinks per day for men or > 2 drinks per day for women as determined by volunteer report

11. Regular use of tobacco (smoking or chewing), e-cigarettes (a.k.a. vapes), nicotine patches, or illicit drugs over past 6 months as determined by volunteer report. Subjects may also be excluded based on a urine drug test.

12. Psychological conditions as determined by volunteer report such as (but not limited to) eating disorders, depression, bipolar disorders, that would be incompatible with safe and successful participation in this study, as determined by investigators

13. Volunteers with strict dietary concerns (e.g. vegetarian or kosher diet, food allergies) or a reported dislike of a significant fraction of the study foods

14. Unwilling or unable to comply with or perform all study procedures (e.g. cycling or activities of daily living), or unavailability for the duration of the study, as determined by participant or investigator discretion

15. Unwilling or unable to adhere to Lifestyle Considerations throughout study duration, as determined by participant or investigator discretion

16. Volunteers unwilling or unable to give informed consent


--Back to Top--

Citations:

Hall KD, Chen KY, Guo J, Lam YY, Leibel RL, Mayer LE, Reitman ML, Rosenbaum M, Smith SR, Walsh BT, Ravussin E. Energy expenditure and body composition changes after an isocaloric ketogenic diet in overweight and obese men. Am J Clin Nutr. 2016 Aug;104(2):324-33. doi: 10.3945/ajcn.116.133561. Epub 2016 Jul 6. PMID: 27385608; PMCID: PMC4962163.

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

Kevin Hall, Ph.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institutes of Health
Building 12A
Room 4007
12 South Drive
Bethesda, Maryland 20892
(301) 402-8248
kevinh@niddk.nih.gov

Nan Zhai, C.R.N.P.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIHBC 10 - CLINICAL CENTER BG RM 8C432B
10 CENTER DR
BETHESDA MD 20892
(301) 827-3324
nan.zhai@nih.gov

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: TTY Users Dial 7-1-1
ccopr@nih.gov

Clinical Trials Number:

NCT06044935

--Back to Top--